Stoke Therapeutics Hits New 52-Week High of $40.22, Up 157.56%

Stoke Therapeutics, Inc. has reached a significant milestone by hitting a new 52-week high of USD 40.22 on March 10, 2026. This achievement underscores the company's remarkable performance over the past year, with a striking increase of 157.56%, significantly outpacing the S&P 500's growth of 20.78% during the same period. As a small-cap player in the Pharmaceuticals & Biotechnology industry, Stoke Therapeutics boasts a market capitalization of USD 1,959 million. The company's price-to-earnings (P/E) ratio stands at 36.00, reflecting its valuation in the market. Additionally, Stoke Therapeutics has a return on equity of 13.17%, indicating its efficiency in generating profits from shareholders' equity. With a price-to-book ratio of 6.36 and a debt-to-equity ratio of -0.80, the company maintains a solid financial position. Notably, Stoke Therapeutics does not offer a dividend yield, focusing instead on reinvesting in its growth. This recent high marks a pivotal moment for the company as it continues to navigate the competitive landscape of the biotechnology sector.